

Highly Efficient, Massively-Parallel Single-Cell RNA-Seq Reveals Cellular States and Molecular Features of Human Skin Pathology

Travis K Hughes^{1,2,3,4,5,9}, Marc H Wadsworth II^{1,3,4,5,9}, Todd M Gierahn^{5,6,9}, Tran Do⁷, David Weiss⁷, Priscilla R. Andrade⁷, Feiyang Ma⁷, Bruno J. de Andrade Silva⁷, Shuai Shao⁸, Lam C Tsoi⁸, Jose Ordovas-Montanes^{1,3,4,5}, Johann E Gudjonsson⁸, Robert L Modlin⁹, J Christopher Love^{3,4,5,6,10}, and Alex K Shalek^{1,2,3,4,5,10}

Affiliations:

¹ Institute for Medical Engineering & Science (IMES) and Department of Chemistry, MIT, Cambridge, Massachusetts, USA

² Department of Immunology, Harvard Medical School, Boston, MA 02115, USA

³ Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

⁴ Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA

⁵ Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts, USA

⁶ Department of Chemical Engineering, MIT, Cambridge, Massachusetts, USA

⁷ Division of Dermatology and Department of Microbiology, Immunology and Molecular Biology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

⁸ Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA

⁹ These authors contributed equally to this work

¹⁰ These senior authors contributed equally to this work

¹⁰ To whom correspondence should be addressed: shalek@mit.edu (AKS), clove@mit.edu (JCL)

1 **SUMMARY**

2 The development of high-throughput single-cell RNA-sequencing (scRNA-Seq) methodologies
3 has empowered the characterization of complex biological samples by dramatically increasing the
4 number of constituent cells that can be examined concurrently. Nevertheless, these approaches
5 typically recover substantially less information per-cell as compared to lower-throughput microtiter
6 plate-based strategies. To uncover critical phenotypic differences among cells and effectively link
7 scRNA-Seq observations to legacy datasets, reliable detection of phenotype-defining transcripts
8 – such as transcription factors, affinity receptors, and signaling molecules – by these methods is
9 essential. Here, we describe a substantially improved massively-parallel scRNA-Seq protocol we
10 term Seq-Well S³ (“Second-Strand Synthesis”) that increases the efficiency of transcript capture
11 and gene detection by up to 10- and 5-fold, respectively, relative to previous iterations, surpassing
12 best-in-class commercial analogs. We first characterized the performance of Seq-Well S³ in cell
13 lines and PBMCs, and then examined five different inflammatory skin diseases, illustrative of
14 distinct types of inflammation, to explore the breadth of potential immune and parenchymal cell
15 states. Our work presents an essential methodological advance as well as a valuable resource
16 for studying the cellular and molecular features that inform human skin inflammation.

17 INTRODUCTION

18 Although a nascent technology, single-cell RNA-sequencing (scRNA-Seq) has already
19 helped define, at unprecedented resolution, the cellular composition of many healthy and
20 diseased tissues (Klein et al., 2015; Macosko et al., 2015; Montoro et al., 2018; Ordovas-
21 Montanes et al., 2018; Vento-Tormo et al., 2018). The development of high-throughput
22 methodologies has been crucial to this process, empowering the characterization of increasingly
23 complex cellular samples. Unfortunately, current scRNA-Seq platforms typically demonstrate an
24 inverse relationship between the number of cells that can be profiled at once and the amount of
25 biological information that can be recovered from each cell. As a result, one must choose between
26 quantity and quality – and thus comprehensiveness and fidelity – or alternatively employ two
27 distinct approaches in parallel (Tabula Muris Consortium et al., 2018). Indeed, inefficiencies in
28 transcript capture among massively-parallel methods have limited our ability to resolve the distinct
29 cell states that comprise broad cell types (Braga et al., 2019), as well as their essential molecular
30 attributes and often lowly-expressed molecular features, such as transcription factors, affinity
31 receptors, and signaling molecules (**Figure 1A**).

32 Improving the fidelity of these methodologies is particularly important for resolving
33 differences within heterogeneous populations of immune cells like lymphocytes and myeloid cells
34 (Villani et al., 2017). Here, subtle differences in surface receptor, transcription factor and/or
35 cytokine expression can profoundly impact cellular function, particularly in the setting of human
36 pathology (Puel et al., 1998). Enhancing data quality in high-throughput scRNA-Seq would
37 facilitate a greater appreciation of the underlying molecular features that describe such cellular
38 variation. Similarly, it would ease integration with legacy datasets that often rely on lowly-
39 expressed biomarkers, such as transcription factors, that are false-negative prone to discriminate
40 subsets of cells.

41 Most high-throughput scRNA-Seq methods currently rely on early barcoding of cellular
42 contents to achieve scale. Typically, these techniques recover single-cell transcriptomes for
43 thousands of cells at once by leveraging reverse-emulsion droplets or microwells to isolate
44 individual cells with uniquely barcoded poly-dT oligonucleotides which can then capture and tag
45 cellular mRNAs during reverse transcription (Prakadan et al., 2017). Afterward, an additional
46 priming site is added to the 3' end of the synthesized cDNA to enable PCR-based amplification
47 of all transcripts using a single primer (whole transcriptome amplification, WTA). A number of
48 techniques have been described to add this second priming site (Sasagawa et al., 2013; Shishkin
49 et al., 2015). The most common uses the terminal transferase activity of certain reverse
50 transcription enzymes to facilitate a “template-switch” from the original mRNA to a second defined
51 oligonucleotide handle (Picelli et al., 2013). While simple to implement, this process has the
52 potential to be highly inefficient, leading to the loss of molecules that have been captured and
53 converted to cDNA but not successfully tagged with a secondary PCR priming site (**Figure 1A**
54 and **S1A**) (Islam et al., 2012; Kapteyn et al., 2010; Zajac et al., 2013).

55 To overcome these limitations, we have developed a new massively-parallel scRNA-Seq
56 protocol we call Seq-Well S³ (for “Second-Strand Synthesis”). Seq-Well S³ increases the
57 efficiency of the second PCR handle addition by amending it through a randomly-primed second-
58 strand synthesis after reverse transcription (**Figure 1A**). Working with cell lines and peripheral
59 blood mononuclear cells (PBMCs), we demonstrate that Seq-Well S³ enables significant
60 improvements in transcript and gene capture across sample types, facilitating studies of complex
61 immune tissues at enhanced resolution (**Figures 1, S1, and S2**).

62 To illustrate the utility of S³, we apply it to generate a resource of single-cell
63 transcriptional states spanning multiple inflammatory skin conditions. Skin represents the largest
64 barrier tissue in the human body and is comprised of numerous specialized cell-types that help
65 maintain both immunological and physical boundaries between our inner and outer worlds

66 (Kabashima et al., 2019). The dermis and epidermis – the two primary compartments of human
67 skin – play complementary roles in tissue structure and function (**Figure 2A**) (Kabashima et al.,
68 2019). The epidermis consists primarily of keratinized epithelial cells, which provide a physical
69 barrier to the outside world; the dermis, meanwhile, provides structural support for the skin, with
70 fibroblasts producing collagen and elastin fibrils along with the other components of the
71 extracellular matrix. Crucially, within the cellular ecosystem of human skin, there are numerous
72 tissue-resident immune and parenchymal cells essential to homeostatic barrier function. Using
73 Seq-Well S³, we examine the cellular composition of normal skin and altered cellular phenotypes
74 in multiple inflammatory skin conditions, including acne, alopecia areata, granuloma annulare,
75 leprosy and psoriasis. With conditions that span autoimmune (alopecia), autoinflammatory
76 (psoriasis), reactive (acne), and granulomatous (granuloma annulare and leprosy) inflammation,
77 we uncover a diverse spectrum of immune and parenchymal cellular phenotypes, as well as their
78 molecular features, across multiple inflammatory skin conditions. Overall, our work presents an
79 essential methodological advance as well as a critical resource for understanding how diverse
80 inflammatory responses can impact a single tissue and the range of cellular phenotypes that are
81 possible upon perturbation.

82

83 **RESULTS**

84 **Second-Strand Synthesis (S³) Leads to Improved Transcript Capture and Gene Detection**

85 We hypothesized that use of “template-switching” to append a second PCR handle during
86 reverse transcription might limit the overall recovery of unique transcripts and genes from
87 individual cells in some massively-parallel scRNA-Seq methods such as Seq-Well and Drop-Seq
88 (Gierahn et al., 2017; Macosko et al., 2015). Thus, we incorporated a randomly primed second-
89 strand synthesis following first-strand cDNA construction (**Figures 1A** and **S1A**). Briefly, after
90 reverse transcription, barcoded mRNA capture beads are washed with 0.1 molar sodium

91 hydroxide to remove attached RNA template strands and then a random second-strand synthesis
92 is performed to generate double-stranded cDNA labeled on one end with the SMART sequence
93 and its reverse complement on the other (**Figure 1A** and **S1A**) (Picelli et al., 2013, 2014).

94 To examine the effectiveness of Seq-Well S³ and optimize its performance, we first
95 tested a number of conditions using cell lines (**Figure S1B**). In these experiments, we observed
96 that S³ led to marked improvements in library complexity (Seq-Well V1: 0.22 transcripts/ aligned
97 read, Seq-Well S³: 0.68 transcripts/ aligned read) and was able to function in the absence of a
98 template switching oligo (TSO); Seq-Well V1, meanwhile, failed to generate appreciable product
99 without a TSO (**Figure S1B-D**). In species-mixing experiments using HEK293 (human) and NIH-
100 3T3 (mouse) cell lines, the use of the S³ protocol resulted in significant increases in the numbers
101 of unique transcripts captured and genes detected per cell compared to our original protocol for
102 Seq-Well ($P < 0.05$, Mann-Whitney U Test; **Figure S1C**).

103 To fully understand how S³ would perform on more challenging primary cells, we next
104 applied it to human PBMCs (**Figure S1C** and **S2**), benchmarking against our original Seq-Well
105 protocol as well as a commercial technology (10X genomics, V2 chemistry; hereafter 10x v2). For
106 these comparisons, we down-sampled all resulting data to an average of 42,000 reads per cell to
107 account for differences in sequencing depth across technologies. Critically, Seq-Well S³ resulted
108 in significant improvements in the complexity of our sequencing libraries compared to 10x v2 as
109 determined by the number of transcripts and genes detected at matched read depth ($P < 0.05$,
110 Mann-Whitney U Test & Linear Regression; **Figure 1B-C**). To confirm that these overall
111 improvements were not driven by changes in the relative frequencies of different cell types
112 captured by each technology, we also examined each subset independently (**Figure S2A-B**). For
113 each cell type detected, we observed significant increases in the numbers of transcripts captured
114 and genes detected using S³ for each pairwise comparison between techniques ($P < 0.05$,
115 Mann-Whitney U Test; CD4⁺ T cells, Seq-Well V1: $1,044 \pm 62.3$ UMIs/cell; 10x v2: $7,671 \pm 103.9$

116 UMIs/cell; Seq-Well S³: 13,390 ± 253.4 UMIs/cell; Mean ± Standard Error of the Median (SEM);
117 **Figure S2**). Both Seq-Well S³ and 10x v2 displayed increased sensitivity for transcripts and
118 genes relative to Seq-Well v1, but Seq-Well S³ showed the greatest efficiency (defined as genes
119 recovered at matched read depth) to detect genes for each cell type (**Figure 1D-E**; **Figure S2**).

120 We sought to further understand whether these improvements resulted in enhanced
121 detection of biologically relevant genes typically under-represented in high-throughput single-cell
122 sequencing libraries (Tabula Muris Consortium et al., 2018). Importantly, genes that were
123 differentially detected (i.e., higher in S³) within each cell type include numerous transcription
124 factors, cytokines and cell-surface receptors (**Figure 1D-E**). For example, among CD4⁺ T cells,
125 we observe significantly increased detection of cytokines (e.g., *TGFB1* and *TNF*), surface
126 receptors (e.g., *TGFBR* and *CCR4*) and transcription factors (e.g., *STAT6*, and *IRF4*) ($P < 0.05$,
127 Chi-Square Test, **Figure 1H** and **S2**).

128 Finally, we performed an additional comparison of enriched human CD4⁺ T cells profiled
129 using Seq-Well S³ and 10X v2, as well as by Smart-Seq2, a commonly implemented microtiter
130 plate-based approach (**Figure 1F-G**) (Picelli et al., 2013). Integrated analysis of aggregate gene
131 detection revealed that Seq-Well S³ detects more genes per cell than 10x v2 and nearly as many
132 genes per cell as Smart-Seq2 in pairwise comparison of techniques (10x v2: 2,057 ± 18.7
133 genes/cell, Seq-Well S³: 3,514 ± 36.2 genes/cell, SS2: 3,975 ± 74.0 genes/cell; mean ± SEM;
134 $P < 0.05$, Mann-Whitney Test; **Figure 1F**). Further, comparing the frequency of gene detection
135 between methods revealed crucial differences for transcription factors, cytokines and
136 receptors/ligands. Surprisingly, we observe similar rates of gene detection between S³ and
137 Smart-Seq2 for a large number of biologically informative genes (**Figure S2F**). Critically, while
138 comparable numbers of genes were detected across methods, Seq-Well S³ detected more
139 genes per aligned read than either 10x v2 or SS2 in pairwise comparisons ($P < 0.05$, Mann-
140 Whitney U Test; **Figure 1G**).

141 **A Resource of Cellular States Across Healthy and Inflamed Skin**

142 To demonstrate the utility of Seq-Well S³ to comprehensively describe cellular states
143 across human pathology at unprecedented resolution, we applied it to profile human skin samples
144 spanning multiple, complex inflammatory skin conditions (**Figure 2**) – including acne, alopecia
145 areata, granuloma annulare, leprosy, psoriasis – as well as normal skin (**Figure 2A-B** and **S3A-**
146 **C**). In total, we processed nine skin biopsies by S³ and, after data quality filtering, retained
147 20,308 high-quality single-cell transcriptomes (**Figure 2A-B**).

148 To examine similarities and differences among these cells across the high-dimensional
149 gene expression space, we selected variable genes, performed UMAP dimensionality reduction,
150 and identified 33 clusters through Louvain clustering in Scanpy (Wolf et al., 2018) (**Figure 2** and
151 **S3A-C**). To collapse clusters to cell-types, we performed enrichment analyses to identify cluster-
152 defining genes (**Figure S3B**) and then manually assigned cell-type identities based on the
153 expression of known lineage markers (**Figure 2C**). We also generated aggregate gene
154 expression profiles and performed hierarchical clustering using a combined list of the top 50
155 cluster-defining genes for each cluster to further support our annotations and groupings (**Figure**
156 **S3C**). Ultimately, we recovered a total of 16 primary cell-types, within which there was
157 considerable heterogeneity. The identified cell types include: B cells (marked by expression of
158 *MS4A1* and *CD79A*), dendritic cells (*FCER1G* and *CLEC10A*), endothelial cells (*SELE* and
159 *CD93*), fibroblasts (*DCN* and *COL6A2*), hair follicles (*SOX9*), keratinocytes (*KRT5* and *KRT1*),
160 macrophages (*CD68* and *CTSS*), mast cells (*CPA3* and *IL1RL1*), muscle (*NEAT1* and
161 *KCNQ1OT1*), plasma cells (*IGHG1*), Schwann cells (*SCN7A*), and T cells (*CD3D* and *TRBC2*)
162 (**Figure 2** and **S3A-D**). We next sought to define nuanced cell states within these immune, stromal
163 and parenchymal populations – including T cells, myeloid cells, endothelial cells, dermal
164 fibroblasts, and keratinocytes – across the spectrum of skin inflammation.

165

166 **Seq-Well S³ describes T cell states across inflammatory skin conditions**

167 To determine the range of biological diversity that can be captured using Seq-Well S³,
168 we first focused on further characterizing T cells across the inflammatory skin conditions
169 examined since each is known to significantly skew T cell phenotypes (**Figure 3**) (Diani et al.,
170 2015; Lowes et al., 2014). We performed dimensionality reduction and sub-clustering across T
171 cells alone (**Figure 3A-B**). Our analysis revealed nine sub-clusters that closely correspond to NK
172 cells and CD8⁺ T cells, as well as several known CD4⁺ T-helper cell (Th) subsets. As before, we
173 used the enhanced sensitivity of S³ for lineage defining transcripts to help annotate the identity
174 of each sub-cluster; for example, in T cell sub-clusters 5 and 6, respectively, we detected distinct
175 expression of canonical regulatory T cell and Th-17 T cell transcription factors (e.g., *FOXP3* and
176 *RORC*, respectively) and immune receptors (e.g. *TIGIT* and *CXCR6* respectively) (**Figure 3C-E**
177 and **S4**). Additionally, we cross-referenced each sub-cluster's marker genes against a series of
178 curated signatures in the Savant database (Lopez et al., 2017) to confirm our assignments. This
179 analysis highlighted similarity to previously characterized T cell and NK cell populations (**Figure**
180 **S4C**).

181 We next examined T cell phenotypes across inflammatory skin conditions to explore
182 variability in T cell subset composition by skin pathology (**Figure 3B**). This analysis revealed
183 potentially varied contributions to different classes of cutaneous inflammation. For example, sub-
184 cluster 6 is enriched for expression of canonical Th-17 genes including *RORC*, which encodes
185 the Th-17 lineage-defining transcription factor ROR γ t (Ivanov et al., 2006) and is observed
186 predominantly within the leprosy sample. While either Th1 or Th2 responses are typically thought
187 to predominate in the immune response to leprosy, a role for Th-17 cells in controlling disease
188 has been previously demonstrated (Saini et al., 2013, 2016). We further found that sub-cluster 1,
189 which express *NR4A1*, a transcription factor that is a marker of dysfunctional T cells (Liu et al.,
190 2019), and sub-cluster 3, enriched for genes involved in nuclear organization (*ANKRD36*, *XIST*,

191 and *NEAT1*), were over-represented in both patients from psoriasis (**Figure 3B-C**). In alopecia
192 areata, we detected a unique population of T cells (sub-cluster 7) that overexpress *PDE4D*, which
193 has been shown to play a role in TCR-dependent T cell activation (**Figure 3D**) (Peter et al.,
194 2007).

195 We also uncovered considerable variation across cytotoxic T cells and NK cells. Directed
196 analysis within CD8⁺ T cells (sub-cluster 0) revealed a sub-grouping of activated CD8⁺ T cells that
197 express elevated levels of several inflammatory cytokines (*TNF*, *CCL4*, and *XCL1*), as well as
198 specific affinity receptors (*FASLG* and *TNFRSF9*) and transcription factors (*KLF9* and *EGR2*);
199 this phenotypic skewing was observed primarily in a patient with granuloma annulare (**Figure 3F**
200 and **S4B**). Meanwhile, we found the highest degree of cytotoxic gene expression (*GNLY*, *GZMB*,
201 and *PRF1*) among cells in sub-cluster 8, suggesting that this sub-cluster may represent a diverse
202 set of NK cells, $\gamma\delta$ T cells, and activated cytotoxic T cells. Indeed, further analysis of sub-cluster
203 8 revealed 3 distinct component sub-groups of cytotoxic cells: a sub-group of CD8⁺ T cells (T.8.1;
204 *TNFSF8*, *SLAMF1*, *CLEC2D*, *CD5*) expressing various TCR genes; a second sub-group of CD16⁺
205 cells (T.8.2) expressing cytotoxic effector molecules (*GNLY*, *PRF1*, *GZMB*) and NK surface
206 receptors, consistent with either NK cell or tri-cytotoxic CTL (Balin et al., 2018); and a third sub-
207 group of NK cells (T.8.3) enriched for expression of *c-KIT*, *RANKL* (*TNFSF11*) and *GITR*
208 (*TNFSFR18*) (**Figure 3H** and **S4B**) (Söderström et al., 2010).

209 Profiling of T cell receptor expression is critical to understand T cell antigen specificity
210 (Zhang et al., 2018). Importantly, among CD4⁺ T cells obtained from peripheral blood, we
211 recovered most TCR-V and TCR-J genes at a higher frequency using Seq-Well S³ as compared
212 to 10x v2 ($P < 0.05$, Chi-square Test; **Figure S4C**). Among CD4⁺ T cells from peripheral blood, we
213 observed paired detection of TRAC and TRBC in 1,293 of 1,485 CD4⁺ T cells (87.1% Paired
214 Detection Rate, **Figure S4C**). In the setting of skin inflammation, we explored TCR detection rates
215 across a range of sequencing read depths. Overall, we detected *TRAC* in 54.5%, *TRBC* in 75.5%,

216 and paired detection in 46.4% of T cells (**Figure 3G**). Among T cells with at least 25,000 aligned
217 reads, we recovered paired α and β chains in 66.7%. Among cells from sub-cluster 8, we observe
218 expression of γ and δ constant genes (*TRGC* and *TRDC*), while remaining T cell clusters
219 exclusively express α and β TCR constant genes (**Figure S4C**). These data further suggest that
220 sub-cluster 8 represents a diverse population of $\gamma\delta$, NK, and cytotoxic CD8⁺ T cells that share
221 common gene expression features and, potentially, roles in inflammation.

222

223 **Spectrum of Myeloid Cell States in Skin Inflammation**

224 In the setting of cutaneous inflammation, myeloid cells play a key role in maintaining tissue
225 homeostasis, wound healing and response to pathogens (Malissen et al., 2014). Using Seq-Well
226 S³, we were able to identify numerous myeloid cell subpopulations defined by a combinations
227 of surface markers, cytokines and lineage-defining transcription factors. Specifically, we
228 independently analyzed 2,371 myeloid cells and identified nine sub-clusters representing 4
229 primary myeloid cell types based on expression of canonical lineage markers and comparison to
230 cell-type signatures in the Savant database: dendritic cells (*CLEC10A*), Langerhans cells (*CD207*
231 and *CD1A*), macrophages (*CD68* and *CD163*), and mast cells (*CPA3* and *TPSAB1*) (**Figure 4A**
232 and **S4D-E**) (Lopez et al., 2017).

233 Among the macrophages, our data reveal two distinct sub-clusters (**Figure 4A-B**). One
234 macrophage sub-cluster spans normal skin as well as multiple types of skin inflammation and is
235 characterized by elevated expression of previously characterized markers of dermal
236 macrophages (*CD163*, *STAB1*, and *CEPP*) (Fuentes-Duculan et al., 2010). The second sub-
237 cluster, meanwhile, is observed uniquely in leprosy and defined by genes involved in extracellular
238 proteolysis (*LYZ*, *CHIT1*, and *CHI3L1*) (Di Rosa et al., 2013).

239 Skin functions as both a physical and immunologic barrier, and is the primary site of
240 exposure to environmental antigens. As such, multiple types of antigen-presenting cells (APCs)
241 are distributed in both the dermis and epidermis. In the epidermis, there is a specialized population
242 of antigen-presenting cells known as Langerhans cells. We initially identified Langerhans cells on
243 the basis of expression of canonical markers (*CD207*, *CD1A*; **Figure 4C-D**) (Romani et al., 2003).
244 For biopsies obtained from normal skin and leprosy, we performed MACS enrichments from the
245 epidermal section and loaded Langerhans cells as 5% of the total amount to increase recovery.
246 When we directly compared Langerhans cells from leprosy and normal skin, we observed
247 elevated expression of *IDO1*, *STAT1*, *HICAR3* and MHC class I molecules (*HLA-A*, *HLA-B* and
248 *HLA-F*) in Langerhans cells in leprosy infection, which may suggest a role for Langerhans cells in
249 priming CD8⁺ T cell responses in this disease (**Figure 4E**) (Hunger et al., 2004; Pinheiro et al.,
250 2018).

251 Additionally, we found a large sub-group of dermal dendritic cells (**Figure 4A**). Further
252 analysis of the *CD207*⁻ dendritic cell sub-cluster revealed multiple sub-groupings of dermal
253 dendritic cells across skin biopsies. Consistent with previous observations from peripheral blood
254 (Villani et al., 2017), we saw a sub-group of dendritic cells that corresponds to cDC1 (*CLEC9A*,
255 *IRF8*, and *WDFY4*) ($P < 0.05$, Permutation Test, **Figure S4H**). We further report another sub-group
256 that represents cDC2 cells (*IRF4*, *SOCS2*, *SLCO5A1*, *CD1B*, *CD1E*) (**Figure 4B-C** and **Figure**
257 **S4F-H**) (Guilliams et al., 2016). Importantly, we detect expression of IL12B, a subunit of the IL-23
258 cytokine, within the sub-group of IRF4⁺ cDC2 cells (**Figure S4I-J**), which have previously been
259 shown to promote mucosal type 17 inflammation via secretion of IL-23 (Schlitzer et al., 2013).
260 Further, this sub-grouping of cDC2 cells express high levels of *CCL17* and *CCL22*, chemokines
261 involved in T cell chemotaxis (**Figure S4J**) (Stutte et al., 2010).

262 We further identified three sub-groups of dermal dendritic cells that are broadly
263 distinguished from conventional dendritic cell clusters by expression of *CLEC10A* (**Figure S4J**),

264 which has been shown to influence T cell cytokine responses in skin (Kashem et al., 2015;
265 Kumamoto et al., 2013). Cells from dermal DC sub-group 1 show elevated expression of *CD44*,
266 *IL8* and *SOD2* (**Figure S4I**). Cells from dermal DC sub-group 2 display elevated expression of
267 pro-inflammatory chemokines up-regulated during DC maturation (*CXCL3*, *CCL2* and *CCL4*) (Jin
268 et al., 2010) and soluble mediators (*EREG* and *INHBA*). Finally, a third sub-grouping of dermal
269 DCs (Dermal DC3) was distinguished by expression of *FCER1A*, *FCGR2A*, and *FCGR2B*, which
270 are important for interfacing with humoral immunity (**Figure S4I**) (Guilliams et al., 2014).

271 In the skin, mast cells are most commonly associated with allergic responses, but mast
272 cell proteases serve additional roles in inflammation and pathogen defense (Pejler et al., 2010).
273 Among skin mast cells, we detect core expression of *HDC* (Histidine decarboxylase), *HPGD*, and
274 *TPSAB1* (Tryptase α/β 1) (**Figure 4F**) (Dwyer et al., 2016). Importantly, we observe variable
275 expression of mast cell proteases *TPSD1* (Tryptase D1) and *CMA1* (Chymase A1), which are
276 primary mast cells effector molecules (Pejler et al., 2010), which may have functional
277 consequences. By performing analysis across inflammatory conditions and patients, we identify
278 a distinct pattern of mast cells with elevated expression of proteases (*TPSD1*, Tryptase D1 and
279 *PRSS27*, serine protease 27), *SCG2* (secretogranin 2), and *CCL2* in a patient with granuloma
280 annulare (**Figure 4F**).

281

282 **Detection of Endothelial Heterogeneity and Vascular Addressin Expression**

283 Multiple types of endothelial cells exist within the dermis of the skin. As in most tissues,
284 arterioles shuttle oxygenated blood to tissues terminating in a capillary bed that gives rise to post-
285 capillary venules. Importantly, DARC⁺ post-capillary venules are the primary site of egress of
286 immune cells from circulation into tissues (Schön et al., 2003). Using the improved sensitivity of
287 Seq-Well S³, we sought to understand the spectrum of endothelial cell diversity and vascular
288 addressin expression across multiple instances of skin inflammation (von Andrian and Mempel,

289 2003). We performed sub-clustering and dimensionality reduction across 4,996 endothelial cells
290 (**Figure S5A-B**) and identified three primary sub-clusters of dermal endothelial cells defined by
291 distinct expression patterns: vascular smooth muscle (*TAGLN*), endothelial cells (*CD93*) and
292 lymphatic endothelial cells (*LYVE1*) (**Figure S5C**). Importantly, we found multiple sub-clusters of
293 *CD93*⁺ endothelial across normal and inflamed skin biopsies (**Figure S5A-B**). For example, we
294 observe two distinct populations of endothelial cells: a population of *DARC*⁻, *CD93*⁺ endothelial
295 cells (Venule sub-cluster 3) that displays elevated expression of *SLC9A3R2*, which is involved in
296 endothelial homeostasis (Bhattacharya et al., 2012), and another cluster of proliferating
297 endothelial cells (Venule sub-cluster 4) (**Figure S5D**).

298 Further, we sought to understand the distribution of vascular addressins expressed by
299 *DARC*⁺ endothelial sub-populations, the site primary site of lymphocyte egress into tissues
300 (**Figure S5E**) (Thiriou et al., 2017). Notably, across sub-populations of *CD93*⁺ endothelial cells
301 (Venule sub-clusters 1-4), we observe variation in expression of vascular addressins (**Figure**
302 **S5E**). Among post-capillary venules, we observe broadly elevated expression of *ITGA5*, *ITGA6*,
303 *ITGB4*, *ICAM2*, and *ITGA2*, while arterioles express higher levels of *ITGA7*, *ITGA8*, and *ITGB5*.
304 Further, we observe the highest expression of *ITGA4*, *ITGA9*, *ITGB2* and *ITGB8* among lymphatic
305 endothelial cells (**Figure 5E**).

306

307 **Altered Dermal Fibroblast Identities in Skin Inflammation**

308 Dermal fibroblasts provide structural support and are the primary source of extracellular
309 matrix components within the skin. Previous studies have demonstrated significant variation
310 among dermal fibroblasts based on their relationship to anatomic features of the skin (Driskell
311 and Watt, 2015; Driskell et al., 2013). To deeply catalogue diverse fibroblast cell states across
312 inflamed skin, we performed dimensionality reduction and sub-clustering within the 4,189
313 fibroblasts identified across all samples and conditions (**Figure S5F-G**). In comparison to inflamed

314 biopsies, fibroblasts from normal skin display enrichments in *LTBP4*, *IGFBP5*, and *TCF4*.
315 Consistent with previous single-cell studies of dermal fibroblasts, we observe a sub-population of
316 fibroblasts (Cluster 6) that express *COL11A1*, *DPEP1* and *RBP4*, where these cells were
317 suggested to have a role in connective tissue differentiation (**Figure S5H**) (Tabib et al., 2018).

318 Fibroblasts from GA patient 1 (sub-cluster 2) express elevated levels of *SPOCK1*, *CRLF1*,
319 and *COMP*, a cartilage protein that is upregulated in matrix-producing fibroblasts following
320 myocardial infarction (Fu et al., 2018) (**Figure S5H-I**). Further, fibroblasts from GA patient 2 (sub-
321 cluster 0) display elevated expression of protease inhibitor 16 (*PI16*), which inhibits the function
322 of MMP2 (Hazell et al., 2016), and *ITIH5*, a protease inhibitor important for maintenance of dermal
323 hyaluronic acid that is overexpressed in skin inflammation (**Figure S5H-I**) (Huth et al., 2015).
324 Finally, among fibroblasts from acne patients, we observed elevated expression of multiple
325 metallothioneins (**Figure S5H-I**). Specifically, the expression levels of *MT1E* and *MT2A* are
326 highest in fibroblasts and endothelial cells in acne (**Figure S5H**). As seen among endothelial cells,
327 fibroblast expression patterns in acne are consistent with a wound healing response (Iwata et al.,
328 1999).

329 **Keratinocyte Differentiation Trajectories**

330 Within the epidermis, keratinocytes undergo a stereotyped differentiation process in which
331 cells acquire altered morphology and phenotype as they mature (**Figure 5A**) (Fuchs, 1990).
332 Under physiologic conditions, basal keratinocytes are characterized by expression of *KRT14* and
333 *TP63*, and continuously divide to give rise to the remaining cells of the epidermis (Fuchs and
334 Raghavan, 2002). Using keratinocytes from normal skin, we performed pseudo-temporal analysis
335 to reconstruct the differentiation process of normal epidermal keratinocytes (**Figure 5D**). More
336 specifically, in normal skin, we first identified a population of keratinocytes enriched for expression
337 of *TP63* and *KRT14*, markers of basal keratinocytes (**Figure S6B**) (Pellegrini et al., 2001). We
338 then used known patterns of cytokeratin expression to infer localization of keratinocytes along a

339 supervised differentiation trajectory (**Figure 5E** and **S6A**) (Ordovas-Montanes et al., 2018). Our
340 trajectory analysis revealed patterns of transcription factor and cytokeratin expression that closely
341 correspond to previously established signatures of keratinocyte maturation (Cheng et al., 2018).
342 Consistent with immunohistochemical staining from the Human Protein Atlas (**Figure 5E**) (Uhlén
343 et al., 2015), we observed enrichment of filaggrin (*FLG*), a protein in the outer layers of the
344 epidermis (Sandilands et al., 2009), *mRNA* among keratinocytes that lie at the terminal points in
345 the pseudo-temporal ordering (**Figure 5E** and **Figure S6B**).

346 Having established a trajectory for normal keratinocyte differentiation, we next examined
347 patterns of keratinocyte differentiation across pathologic conditions. To identify conserved and
348 unique patterns across conditions, we constructed a combined diffusion map using the 5,141
349 keratinocytes recovered across all samples (**Figure 5C**). While keratinocytes from most
350 conditions closely align with normal differentiation, we observe marked deviation in the
351 differentiation trajectory of psoriatic keratinocytes (**Figure 5C**). Consistent with previous
352 observations, differential expression analysis reveals significant up-regulation of antimicrobial
353 peptides (*S100A7*, *S100A8*, *S100A9*) and pro-inflammatory cytokines (*IL36G*, *IL36RN*) in
354 psoriatic keratinocytes (Li et al., 2014).

355 Based on increased sensitivity of Seq-Well S³ to detect transcription factors observed in
356 peripheral lymphocytes, we hypothesized that our data might enable identification of novel
357 transcriptional regulators of psoriatic keratinocytes. To identify potential drivers of the psoriatic
358 disease process within the epidermis, we performed differential pseudo-time correlation analysis
359 between psoriatic and normal keratinocytes. Specifically, we separately constructed pseudo-time
360 trajectories for normal and psoriatic keratinocytes, calculated correlation values between diffusion
361 pseudo-time and gene expression levels, and examined the difference in correlation values
362 between psoriatic and normal keratinocytes (**Figure 5F** and **S6A-B**). Notably, we observed
363 positive correlation of *FOSL1*, an AP-1 transcription factor, with diffusion pseudo-time in psoriatic

364 keratinocytes, implying that *FOSL1* is preferentially expressed along the differentiation trajectory
365 of psoriatic keratinocytes. To validate this observation, we performed immunofluorescence
366 staining for FOSL1 protein, and measured increased levels of FOSL1 in psoriatic skin (**Figure**
367 **5G**). We further validated the distribution of additional genes overexpressed or differentially
368 correlated with diffusion pseudo-time in psoriatic keratinocytes (including *TNFAIP3*, *IL36G*, and
369 *APOBEC3*) at the protein level (**Figure 5G and S6A**).

370 To further define differences in gene expression patterns between normal and psoriatic
371 keratinocytes, we scored the expression levels of known cytokine response signatures using a
372 series of reference signatures gene lists derived from population RNA-Seq of cultured
373 keratinocytes exposed to IL-17A (**Figure S6C**). While IL-17 has been previously implicated in the
374 pathogenesis of psoriasis, here we infer the identity of cells that dominate the IL-17 response,
375 localizing the expression of IL-17 responsive genes to spinous keratinocytes (Ordovas-Montanes
376 et al., 2018). To validate this observation, we performed immunofluorescent staining for IL-17R
377 protein and measured the highest staining within spinous keratinocytes exclusively within psoriatic
378 skin (**Figure 5H**). Collectively, these data provide novel insights into the localization IL-17
379 response in psoriatic keratinocytes.

380

381 **DISCUSSION**

382 Here, we present an enhanced technique for high-throughput scRNA-Seq – Seq-Well S³
383 – that affords improved sensitivity for transcript capture and gene detection. Through use of a
384 templated second-strand synthesis, S³ recovers information typically lost in bead-based high-
385 throughput scRNA-Seq protocol such as Seq-Well or Drop-Seq. Specifically, S³ reclaims mRNA
386 molecules that are successfully captured and reverse transcribed but not labeled with a second
387 primer sequence through template switching (**Figure 1 and S1**). Using Seq-Well S³, we obtain
388 a 5-10 fold increase in the number of unique molecules captured from cells at similar sequencing

389 depth relative Seq-Well v1 (**Figures 1, S1 and S2**) (Gierahn et al., 2017). Beyond aggregate
390 increases in the number of transcripts recovered per-cell, the improvements in sensitivity made
391 possible by Seq-Well S³ enable enhanced detection, and thus deeper examination, of lineage-
392 defining factors in immune and parenchymal cells – such as transcription factors, cytokines, and
393 cytokine receptors among lymphocytes (**Figure 1 and S2**) – which are often transiently or lowly
394 expressed (Zhu et al., 2010). Among CD4⁺ T cells isolated from PBMCs, for example, we
395 observed rates of gene detection similar to those observed in Smart-Seq2, a best-in-class
396 microtiter plate-based method (**Figure 1F-G and S2F**).

397 Similarly, using Seq-Well S³, we report improved paired detection of α and β TCR
398 sequences from T cells in peripheral blood and tissue biopsies (**Figures 3G and S4C**). Among
399 CD4⁺ T cells from PBMCs, we recover paired TCR α and β constant genes in 87.1% of cells.
400 Together with targeted enrichment, amplification and sequencing, we anticipate that Seq-Well
401 S³ will enable improvements in TCR reconstruction and deep characterizations of clonotype-
402 phenotype relationships at scale (Zhang et al., 2018). Collectively, our validation experiments
403 show that Seq-Well S³ significantly augments the amount of information that can be recovered
404 in massively-parallel scRNA-seq experiments, enabling high-resolution profiling of low-input
405 biopsy samples at scale.

406 With this enhanced method, here, we move towards a draft atlas of human skin
407 inflammation by creating a compendium of cell-types and states for the broader research
408 community (Regev et al., 2018). Through use of Seq-Well S³, we survey, at unprecedented
409 resolution, the diversity of cell-types and states – e.g., among tissue resident T cells and myeloid
410 cells – present across multiple types of skin inflammation. For example, GA and leprosy are two
411 granulomatous diseases characterized by aggregates of lymphocytes and macrophages within
412 the dermis, which are both thought to arise from a delayed-type hypersensitivity response to *M.*
413 *leprae* infection (leprosy) and an unknown agent (GA) (Modlin et al., 1984; Terziroli Beretta-Piccoli

414 et al., 2018). Here, we find that both are characterized by the presence of T cell sub-cluster 0
415 (Immature CD8⁺ CTL) and T cell sub-cluster 8 (mature CTL effectors containing CD8⁺ T-CTL, $\gamma\delta$
416 and NK cells; **Figure 3**). Although both conditions contain CD163⁺ dermal macrophages and
417 various DC subpopulations, M1-like macrophages were present only in leprosy, which host the
418 intracellular pathogen *M. leprae*, were present only in leprosy (Fulco et al., 2014; Verreck et al.,
419 2004). Moreover, GA uniquely contained specific populations of fibroblasts expressing *SPOCK1*,
420 *CRLF1*, and *COMP* (**Figure S5**), which likely reflect remodeling of the dermis with mucin
421 deposition and alternation of elastin fibers (Piette and Rosenbach, 2016; Yun et al., 2009).

422 Acne, meanwhile, is an inflammatory disease thought to arise in response to infection with
423 *P. acnes*, resulting in the formation of lesions that resemble a wound following eruption of the hair
424 follicle into the dermis (Beylot et al., 2014). Here, we observe 2 clusters of endothelial cells marked
425 by expression of *SLC9A3R2*, a marker of endothelial homeostasis, and a signature of proliferation
426 (**Venule clusters 3 and 4, Figure S5**). This increased angiogenesis and endothelial proliferation
427 is most consistent with the proliferative phase of wound healing in acne (Holland et al., 2004).

428 Alopecia areata and psoriasis both arise from autoimmune and autoinflammatory
429 processes, yet there were distinct differences in their underlying cell states. For example, alopecia
430 areata is thought to be driven by a population of CD8⁺ T cells that target hair follicles (Xing et al.,
431 2014). Notably, in alopecia, we report a sub-cluster of T cells characterized by expression of
432 *PDE4D* (**Figure 3**). PDE4 inhibitors have recently shown demonstrated efficacy in the treatment
433 of alopecia (Keren et al., 2015; López et al., 2017), and it is intriguing to speculate that these
434 inhibitors might work by targeting this subset of T cells.

435 In psoriasis, T cells are thought to be a primary driver of inflammation, with dendritic cells
436 playing a central role in the recruitment and polarization of T cells that contribute to the
437 hyperproliferation of keratinocytes in the disease (Lowe et al., 2014). In both patients with
438 psoriasis, we report a sub-cluster of DCs (IRF4⁺ cDC2) that display elevated expression of

439 *CCL17*, *CCL22* and *IL12B* (**Figure 4G** and **Figure S4I**). Importantly, a similar population of dermal
440 cDC2 cells has recently been shown to drive psoriatic inflammation in mice and humans through
441 the recruitment of inflammatory T cells (Kim et al., 2018; Zaba et al., 2010). Although we detected
442 a diversity in T cell subtypes in psoriatic lesions, we note few Th-17-like cells (Hawkes et al.,
443 2018).

444 Leveraging the increased sensitivity of Seq-Well S³, we performed pseudo-time
445 correlation analysis to uncover an altered differentiation trajectory of keratinocytes compared to
446 normal skin (**Figure 5** and **S6**). From our pseudo-time correlation analysis, we detected FOSL1
447 as a putative transcription factor involved in psoriatic differentiation, a finding which we validated
448 through immunofluorescent staining of healthy and psoriatic skin (**Figure 5G**). Further, previous
449 studies using *in vitro* keratinocyte based systems have suggested that more differentiated
450 keratinocytes were the main responders to IL-17A, given larger effect sizes in differentiated
451 compared to monolayer keratinocyte (Chiricozzi et al., 2014). Using data generated with Seq-Well
452 S³ cross-analyzed against an IL-17 response signature in keratinocytes, we show that IL-17
453 responses are observed in keratinocytes from all layers of the epidermis, but that these responses
454 are stronger in keratinocytes derived from more differentiated layers of the psoriatic epidermis
455 (**Figure S6C**). This observation is corroborated by co-localization of the IL-17 receptor subunits
456 (IL-17RA/IL-17RC) in the upper layers of psoriatic epidermis (**Figure 5H**).

457 In conclusion, we describe a powerful massively-parallel scRNA-Seq protocol that enables
458 improved transcript capture and gene detection from low-input clinical samples. Here, Seq-Well
459 S³ provides novel insights into putative mechanisms and the cellular localization of previously
460 appreciated and unknown responses to specific inflammatory mediators in immunologic skin
461 conditions in a fashion not previously achievable. Increases in the sensitivity of gene and
462 transcript detection are increasingly important as single-cell atlasing efforts shift from detection of
463 large differences between cell types within normal tissue to identification of subtle differences in

464 cell state across cell types within diseased tissues. The increased sensitivity of gene detection
465 and transcript capture afforded by S³ enhances the strength of inferences that can be drawn
466 from these types of single-cell data, as evidenced by the range of immune, stromal and
467 parenchymal cell states uncovered in human skin inflammation. The S³ protocol is easy to
468 integrate into current bead-based RNA-Seq platforms, such as Drop-Seq, making it broadly useful
469 for the single-cell community, particularly in the setting of human disease. Importantly, S³'s
470 increases in library complexity and sequencing efficiency reduce costs relative to plate-based
471 protocols, and providing researchers with a powerful and cost-effective alternative to commercial
472 solutions in a format that can be deployed almost anywhere.

473 **ACKNOWLEDGEMENTS**

474 This work was supported in part by the Koch Institute Support (core) NIH Grant P30-CA14051
475 from the National Cancer Institute, as well as the Bridge Project, a partnership between the Koch
476 Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center.
477 This work was also supported by the Food Allergy Science Initiative at the Broad Institute and the
478 NIH (5P01AI039671, 5U19AI089992). A.K.S. was supported by the Searle Scholars Program, the
479 Beckman Young Investigator Program, the Pew-Stewart Scholars Program for Cancer Research,
480 a Sloan Fellowship in Chemistry, the NIH (1DP2GM119419, 2U19AI089992, 2R01HL095791,
481 1U54CA217377, 2P01AI039671, 5U24AI118672, 2RM1HG006193, 1R33CA202820,
482 1R01AI138546, 1R01HL126554, 1R01DA046277, 1U2CCA23319501) and the Bill and Melinda
483 Gates Foundation (OPP1139972, OPP1202327, OPP1137006, and OPP1202327). R.L.M. was
484 supported by the NIH (R01 AI022553, AR040312, AR074302). J.G. is supported by the Taubman
485 Medical Research Institute and the NIH (R01-AR060802, R01-AI30025, and P30-AR075043).
486 T.K.H. is supported by the NIH F30-AI143160.

487

488 **CONTRIBUTIONS**

489 **T.K.H., M.W.H., T.M.G., R.L.M., J.C.L., and A.K.S.** designed the study. **T.K.H., M.H.W., T.D.,**
490 **D.W., P.A., and B.A.** collected skin samples and performed single-cell sequencing experiments.
491 **S.S., L.C.T., and J.E.G.** performed immunofluorescent staining. **T.K.H., M.H.W., T.M.G., and**
492 **F.M.** analyzed data under the guidance of **J.O.M., R.L.M., J.C.L., and A.K.S.** **T.K.H., M.H.W.,**
493 **T.M.G., J.C.L., and A.K.S.** wrote the manuscript with input from all authors.

494

495 **DECLARATION OF INTERESTS**

496 A.K.S, and J.C.L. have received compensation for consulting and SAB membership from
497 Honeycomb Biotechnologies. A.K.S. has received compensation for consulting and SAB
498 membership from Cellarity, Cogen Therapeutics, and Dahlia Biosciences. T.M.G., T.K.H.,
499 M.H.W., A.K.S., and J.C.L are co-inventors on a provisional patent application filed by MIT relating
500 to the improved methodology described in this manuscript.

501

502 **REFERENCES**

- 503 Von Andrian, U.H., and Mempel, T.R. (2003). Homing and cellular traffic in lymph nodes. *Nat.*
504 *Rev. Immunol.* **3**, 867.
- 505 Balin, S.J., Pellegrini, M., Klechevsky, E., Won, S.T., Weiss, D.I., Choi, A.W., Hakimian, J., Lu,
506 J., Ochoa, M.T., Bloom, B.R., et al. (2018). Human antimicrobial cytotoxic T lymphocytes,
507 defined by NK receptors and antimicrobial proteins, kill intracellular bacteria. *Sci. Immunol.* **3**,
508 eaat7668.
- 509 Beylot, C., Auffret, N., Poli, F., Claudel, J.-P., Leccia, M.-T., Giudice, P.D., and Dreno, B.
510 (2014). Propionibacterium acnes: an update on its role in the pathogenesis of acne. *J. Eur.*
511 *Acad. Dermatol. Venereol.* **28**, 271–278.
- 512 Bhattacharya, R., Wang, E., Dutta, S.K., Vohra, P.K., E, G., Prakash, Y.S., and Mukhopadhyay,
513 D. (2012). NHERF-2 maintains endothelial homeostasis. *Blood* **119**, 4798–4806.
- 514 Braga, F.A.V., Kar, G., Berg, M., Carpaij, O.A., Polanski, K., Simon, L.M., Brouwer, S., Gomes,
515 T., Hesse, L., Jiang, J., et al. (2019). A cellular census of human lungs identifies novel cell
516 states in health and in asthma. *Nat. Med.* **1**.
- 517 Cheng, J.B., Sedgewick, A.J., Finnegan, A.I., Harirchian, P., Lee, J., Kwon, S., Fassett, M.S.,
518 Golovato, J., Gray, M., Ghadially, R., et al. (2018). Transcriptional Programming of Normal and
519 Inflamed Human Epidermis at Single-Cell Resolution. *Cell Rep.* **25**, 871–883.
- 520 Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I.,
521 Bonifacio, K.M., Gulati, N., Mitsui, H., Guttman-Yassky, E., Suárez-Fariñas, M., et al. (2014). IL-
522 17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis
523 Model. *PLOS ONE* **9**, e90284.
- 524 Di Rosa, M., Malaguamera, G., De Gregorio, C., Drago, F., and Malaguamera, L. (2013).
525 Evaluation of CHI3L1 and CHIT-1 Expression in Differentiated and Polarized Macrophages.
526 *Inflammation* **36**, 482–492.
- 527 Diani, M., Altomare, G., and Reali, E. (2015). T cell responses in psoriasis and psoriatic arthritis.
528 *Autoimmun. Rev.* **14**, 286–292.
- 529 Driskell, R.R., and Watt, F.M. (2015). Understanding fibroblast heterogeneity in the skin. *Trends*
530 *Cell Biol.* **25**, 92–99.
- 531 Driskell, R.R., Lichtenberger, B.M., Hoste, E., Kretzschmar, K., Simons, B.D., Charalambous,
532 M., Ferron, S.R., Herault, Y., Pavlovic, G., Ferguson-Smith, A.C., et al. (2013). Distinct fibroblast
533 lineages determine dermal architecture in skin development and repair. *Nature* **504**, 277–281.
- 534 Dwyer, D.F., Barrett, N.A., Austen, K.F., The Immunological Genome Project Consortium,
535 Dwyer, D.F., Barrett, N.A., Austen, K.F., Kim, E.Y., Brenner, M.B., Shaw, L., et al. (2016).
536 Expression profiling of constitutive mast cells reveals a unique identity within the immune
537 system. *Nat. Immunol.* **17**, 878–887.
- 538 Fuchs, E. (1990). Epidermal differentiation: the bare essentials. *J. Cell Biol.* **111**, 2807–2814.

- 539 Fuchs, E., and Raghavan, S. (2002). Getting under the skin of epidermal morphogenesis. *Nat.*
540 *Rev. Genet.* 3, 199.
- 541 Fuentes-Duculan, J., Suárez-Fariñas, M., Zaba, L.C., Nogales, K.E., Pierson, K.C., Mitsui, H.,
542 Pensabene, C.A., Kzhyskowska, J., Krueger, J.G., and Lowes, M.A. (2010). A subpopulation
543 of CD163-positive macrophages is classically activated in psoriasis. *J. Invest. Dermatol.* 130,
544 2412–2422.
- 545 Fulco, T. de O., Andrade, P.R., Barbosa, M.G. de M., Pinto, T.G.T., Ferreira, P.F., Ferreira, H.,
546 Nery, J.A. da C., Real, S.C., Borges, V.M., Moraes, M.O., et al. (2014). Effect of Apoptotic Cell
547 Recognition on Macrophage Polarization and Mycobacterial Persistence. *Infect. Immun.* 82,
548 3968–3978.
- 549 Gierahn, T.M., Wadsworth li, M.H., Hughes, T.K., Bryson, B.D., Butler, A., Satija, R., Fortune,
550 S., Love, J.C., and Shalek, A.K. (2017). Seq-Well: portable, low-cost RNA sequencing of single
551 cells at high throughput. *Nat. Methods* 14, 395–398.
- 552 Williams, M., Bruhns, P., Saeys, Y., Hammad, H., and Lambrecht, B.N. (2014). The function of
553 Fcγ receptors in dendritic cells and macrophages. *Nat. Rev. Immunol.* 14, 94–108.
- 554 Williams, M., Dutertre, C.-A., Scott, C.L., McGovern, N., Sichen, D., Chakarov, S.,
555 Van Gassen, S., Chen, J., Poidinger, M., De Pijck, S., et al. (2016). Unsupervised High-
556 Dimensional Analysis Aligns Dendritic Cells across Tissues and Species. *Immunity* 45, 669–
557 684.
- 558 Haghverdi, L., Buettner, F., and Theis, F.J. (2015). Diffusion maps for high-dimensional single-
559 cell analysis of differentiation data. *Bioinformatics* 31, 2989–2998.
- 560 Hawkes, J.E., Yan, B.Y., Chan, T.C., and Krueger, J.G. (2018). Discovery of the IL-23/IL-17
561 Signaling Pathway and the Treatment of Psoriasis. *J. Immunol.* 201, 1605–1613.
- 562 Hazell, G.G.J., Peachey, A.M.G., Teasdale, J.E., Sala-Newby, G.B., Angelini, G.D., Newby,
563 A.C., and White, S.J. (2016). PI16 is a shear stress and inflammation-regulated inhibitor of
564 MMP2. *Sci. Rep.* 6, 39553.
- 565 Hunger, R.E., Sieling, P.A., Ochoa, M.T., Sugaya, M., Burdick, A.E., Rea, T.H., Brennan, P.J.,
566 Belisle, J.T., Blauvelt, A., Porcelli, S.A., et al. (2004). Langerhans cells utilize CD1a and langerin
567 to efficiently present nonpeptide antigens to T cells. *J. Clin. Invest.* 113, 701–708.
- 568 Huth, S., Heise, R., Vetter-Kauczok, C.S., Skazik, C., Marquardt, Y., Czaja, K., Knüchel, R.,
569 Merk, H.F., Dahl, E., and Baron, J.M. (2015). Inter-α-trypsin inhibitor heavy chain 5 (ITI5) is
570 overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive
571 knockout mice and murine 3D skin models. *Exp. Dermatol.* 24, 663–668.
- 572 Islam, S., Kjällquist, U., Moliner, A., Zajac, P., Fan, J.-B., Lönnerberg, P., and Linnarsson, S.
573 (2012). Highly multiplexed and strand-specific single-cell RNA 5' end sequencing. *Nat. Protoc.*
574 7, 813–828.
- 575 Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., and
576 Littman, D.R. (2006). The Orphan Nuclear Receptor RORγt Directs the Differentiation Program
577 of Proinflammatory IL-17+ T Helper Cells. *Cell* 126, 1121–1133.


- 578 Kabashima, K., Honda, T., Ginhoux, F., and Egawa, G. (2019). The immunological anatomy of
579 the skin. *Nat. Rev. Immunol.* *19*, 19–30.
- 580 Kapteyn, J., He, R., McDowell, E.T., and Gang, D.R. (2010). Incorporation of non-natural
581 nucleotides into template-switching oligonucleotides reduces background and improves cDNA
582 synthesis from very small RNA samples. *BMC Genomics* *11*, 413.
- 583 Kashem, S.W., Riedl, M.S., Yao, C., Honda, C.N., Vulchanova, L., and Kaplan, D.H. (2015).
584 Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic
585 Cells and Drive Protective Cutaneous Immunity. *Immunity* *43*, 515–526.
- 586 Kim, T.-G., Kim, S.H., Park, J., Choi, W., Sohn, M., Na, H.Y., Lee, M., Lee, J.W., Kim, S.M.,
587 Kim, D.-Y., et al. (2018). Skin-Specific CD301b+ Dermal Dendritic Cells Drive IL-17-Mediated
588 Psoriasis-Like Immune Response in Mice. *J. Invest. Dermatol.* *138*, 844–853.
- 589 Klein, A.M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li, V., Peshkin, L., Weitz,
590 D.A., and Kirschner, M.W. (2015). Droplet Barcoding for Single-Cell Transcriptomics Applied to
591 Embryonic Stem Cells. *Cell* *161*, 1187–1201.
- 592 Kumamoto, Y., Linehan, M., Weinstein, J.S., Laidlaw, B.J., Craft, J.E., and Iwasaki, A. (2013).
593 CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity. *Immunity* *39*, 733–
594 743.
- 595 Li, B., Tsoi, L.C., Swindell, W.R., Gudjonsson, J.E., Tejasvi, T., Johnston, A., Ding, J., Stuart,
596 P.E., Xing, X., Kochkodan, J.J., et al. (2014). Transcriptome Analysis of Psoriasis in a Large
597 Case–Control Sample: RNA-Seq Provides Insights into Disease Mechanisms. *J. Invest.*
598 *Dermatol.* *134*, 1828–1838.
- 599 Liu, X., Wang, Y., Lu, H., Li, J., Yan, X., Xiao, M., Hao, J., Alekseev, A., Khong, H., Chen, T., et
600 al. (2019). Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction.
601 *Nature* *567*, 525.
- 602 Lopez, D., Montoya, D., Ambrose, M., Lam, L., Briscoe, L., Adams, C., Modlin, R.L., and
603 Pellegrini, M. (2017). SaVanT: a web-based tool for the sample-level visualization of molecular
604 signatures in gene expression profiles. *BMC Genomics* *18*.
- 605 Lowes, M.A., Suárez-Fariñas, M., and Krueger, J.G. (2014). Immunology of psoriasis. *Annu.*
606 *Rev. Immunol.* *32*, 227–255.
- 607 Lun, A.T.L., Riesenfeld, S., Andrews, T., Dao, T.P., Gomes, T., Marioni, J.C., and participants in
608 the 1st Human Cell Atlas Jamboree (2019). EmptyDrops: distinguishing cells from empty
609 droplets in droplet-based single-cell RNA sequencing data. *Genome Biol.* *20*, 63.
- 610 Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas,
611 A.R., Kamitaki, N., Martersteck, E.M., et al. (2015). Highly Parallel Genome-wide Expression
612 Profiling of Individual Cells Using Nanoliter Droplets. *Cell* *161*, 1202–1214.
- 613 Malissen, B., Tamoutounour, S., and Henri, S. (2014). The origins and functions of dendritic
614 cells and macrophages in the skin. *Nat. Rev. Immunol.* *14*, 417–428.

- 615 McGinnis, C.S., Murrow, L.M., and Gartner, Z.J. (2018). DoubletFinder: Doublet detection in
616 single-cell RNA sequencing data using artificial nearest neighbors. *BioRxiv* 352484.
- 617 Modlin, R.L., Horwitz, D.A., Jordan, R.R., Gebhard, J.F., Taylor, C.R., and Rea, T.H. (1984).
618 Immunopathologic Demonstration of T Lymphocyte Subpopulations and Interleukin 2 in
619 Graeloma Annulare. *Pediatr. Dermatol.* 2, 26–32.
- 620 Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F., Chen, S.,
621 Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy includes CFTR-
622 expressing ionocytes. *Nature* 560, 319.
- 623 Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb, C.,
624 Wadsworth, M.H., Hughes, T.K., Kazer, S.W., Yoshimoto, E., et al. (2018). Allergic inflammatory
625 memory in human respiratory epithelial progenitor cells. *Nature* 560, 649.
- 626 Pejler, G., Rönnerberg, E., Waern, I., and Wernersson, S. (2010). Mast cell proteases:
627 multifaceted regulators of inflammatory disease. *Blood* 115, 4981–4990.
- 628 Pellegrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., Ponzin, D.,
629 McKeon, F., and Luca, M.D. (2001). p63 identifies keratinocyte stem cells. *Proc. Natl. Acad. Sci.*
630 98, 3156–3161.
- 631 Picelli, S., Björklund, Å.K., Faridani, O.R., Sagasser, S., Winberg, G., and Sandberg, R. (2013).
632 Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat. Methods* 10,
633 1096–1098.
- 634 Picelli, S., Faridani, O.R., Björklund, Å.K., Winberg, G., Sagasser, S., and Sandberg, R. (2014).
635 Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* 9, 171–181.
- 636 Piette, E.W., and Rosenbach, M. (2016). Granuloma annulare: Clinical and histologic variants,
637 epidemiology, and genetics. *J. Am. Acad. Dermatol.* 75, 457–465.
- 638 Pinheiro, R.O., Schmitz, V., Silva, B.J. de A., Dias, A.A., de Souza, B.J., de Mattos Barbosa,
639 M.G., de Almeida Esquenazi, D., Pessolani, M.C.V., and Sarno, E.N. (2018). Innate Immune
640 Responses in Leprosy. *Front. Immunol.* 9.
- 641 Prakadan, S.M., Shalek, A.K., and Weitz, D.A. (2017). Scaling by shrinking: empowering single-
642 cell “omics” with microfluidic devices. *Nat. Rev. Genet.* 18, 345–361.
- 643 Puel, A., Ziegler, S.F., Buckley, R.H., and Leonard, W.J. (1998). Defective IL7R expression in T
644 - B + NK + severe combined immunodeficiency. *Nat. Genet.* 20, 394.
- 645 Regev, A., Teichmann, S., Rozenblatt-Rosen, O., Stubbington, M., Ardlie, K., Amit, I., Arlotta,
646 P., Bader, G., Benoist, C., Biton, M., et al. (2018). The Human Cell Atlas White Paper.
647 ArXiv181005192 Q-Bio.
- 648 Romani, N., Holzmann, S., Tripp, C.H., Koch, F., and Stoitzner, P. (2003). Langerhans cells –
649 dendritic cells of the epidermis. *APMIS* 111, 725–740.
- 650 Sandilands, A., Sutherland, C., Irvine, A.D., and McLean, W.H.I. (2009). Filaggrin in the
651 frontline: role in skin barrier function and disease. *J. Cell Sci.* 122, 1285–1294.

- 652 Sasagawa, Y., Nikaido, I., Hayashi, T., Danno, H., Uno, K.D., Imai, T., and Ueda, H.R. (2013).
653 Quartz-Seq: a highly reproducible and sensitive single-cell RNA sequencing method, reveals
654 non-genetic gene-expression heterogeneity. *Genome Biol.* *14*, 3097.
- 655 Shishkin, A.A., Giannoukos, G., Kucukural, A., Ciulla, D., Busby, M., Surka, C., Chen, J.,
656 Bhattacharyya, R.P., Rudy, R.F., Patel, M.M., et al. (2015). Simultaneous generation of many
657 RNA-seq libraries in a single reaction. *Nat. Methods* *12*, 323–325.
- 658 Söderström, K., Stein, E., Colmenero, P., Purath, U., Müller-Ladner, U., Matos, C.T. de, Tarner,
659 I.H., Robinson, W.H., and Engleman, E.G. (2010). Natural killer cells trigger osteoclastogenesis
660 and bone destruction in arthritis. *Proc. Natl. Acad. Sci.* *107*, 13028–13033.
- 661 Tabib, T., Morse, C., Wang, T., Chen, W., and Lafyatis, R. (2018). SFRP2/DPP4 and
662 FMO1/LSP1 Define Major Fibroblast Populations in Human Skin. *J. Invest. Dermatol.* *138*, 802–
663 810.
- 664 Tabula Muris Consortium, Overall coordination, Logistical coordination, Organ collection and
665 processing, Library preparation and sequencing, Computational data analysis, Cell type
666 annotation, Writing group, Supplemental text writing group, and Principal investigators (2018).
667 Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature* *562*, 367–372.
- 668 Terziroli Beretta-Piccoli, B., Mainetti, C., Peeters, M.-A., and Laffitte, E. (2018). Cutaneous
669 Granulomatosis: a Comprehensive Review. *Clin. Rev. Allergy Immunol.* *54*, 131–146.
- 670 Thiriot, A., Perdomo, C., Cheng, G., Novitzky-Basso, I., McArdle, S., Kishimoto, J.K., Barreiro,
671 O., Mazo, I., Triboulet, R., Ley, K., et al. (2017). Differential DARC/ACKR1 expression
672 distinguishes venular from non-venular endothelial cells in murine tissues. *BMC Biol.* *15*, 45.
- 673 Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson,
674 Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Tissue-based map of the human
675 proteome. *Science* *347*, 1260419.
- 676 Vento-Tormo, R., Efremova, M., Botting, R.A., Turco, M.Y., Vento-Tormo, M., Meyer, K.B., Park,
677 J.-E., Stephenson, E., Polański, K., Goncalves, A., et al. (2018). Single-cell reconstruction of the
678 early maternal–fetal interface in humans. *Nature* *563*, 347.
- 679 Verreck, F.A.W., Boer, T. de, Langenberg, D.M.L., Hoeve, M.A., Kramer, M., Vaisberg, E.,
680 Kastelein, R., Kolk, A., Waal-Malefyt, R. de, and Ottenhoff, T.H.M. (2004). Human IL-23-
681 producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert
682 immunity to (myco)bacteria. *Proc. Natl. Acad. Sci.* *101*, 4560–4565.
- 683 Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M.,
684 Butler, A., Zheng, S., Lazo, S., et al. (2017). Single-cell RNA-seq reveals new types of human
685 blood dendritic cells, monocytes, and progenitors. *Science* *356*, eaah4573.
- 686 Xing, L., Dai, Z., Jabbari, A., Cerise, J.E., Higgins, C.A., Gong, W., de Jong, A., Harel, S.,
687 DeStefano, G.M., Rothman, L., et al. (2014). Alopecia areata is driven by cytotoxic T
688 lymphocytes and is reversed by JAK inhibition. *Nat. Med.* *20*, 1043–1049.
- 689 Young, M.D., and Behjati, S. (2018). SoupX removes ambient RNA contamination from droplet
690 based single cell RNA sequencing data. *BioRxiv* 303727.

- 691 Yun, J.H., Lee, J.Y., Kim, M.K., Seo, Y.J., Kim, M.H., Cho, K.H., Kim, M.B., Lee, W.S., Lee,
692 K.H., Kim, Y.C., et al. (2009). Clinical and Pathological Features of Generalized Granuloma
693 Annulare with Their Correlation: A Retrospective Multicenter Study in Korea. *Ann. Dermatol.* *21*,
694 113–119.
- 695 Zaba, L.C., Fuentes-Duculan, J., Eungdamrong, N.J., Johnson-Huang, L.M., Nogralas, K.E.,
696 White, T.R., Pierson, K.C., Lentini, T., Suárez-Fariñas, M., Lowes, M.A., et al. (2010).
697 Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish
698 inflammatory from resident dendritic cells in patients with psoriasis. *J. Allergy Clin. Immunol.*
699 *125*, 1261-1268.e9.
- 700 Zajac, P., Islam, S., Hochgerner, H., Lönnerberg, P., and Linnarsson, S. (2013). Base
701 Preferences in Non-Templated Nucleotide Incorporation by MMLV-Derived Reverse
702 Transcriptases. *PLOS ONE* *8*, e85270.
- 703 Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang,
704 J.Y., et al. (2018). Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.
705 *Nature* *564*, 268.
- 706 Zhu, J., Yamane, H., and Paul, W.E. (2010). Differentiation of Effector CD4 T Cell Populations.
707 *Annu. Rev. Immunol.* *28*, 445–489.
- 708
- 709

710 **FIGURES AND FIGURE LEGENDS**



711 **Figure 1. Overview of Second Strand Synthesis (S³)**

712 **A.** Conceptual illustration of the molecular features that define immune phenotypes – including
713 transcription factors, cytokines and receptors – as well as the Seq-Well second-strand synthesis
714 method (Seq-Well S³) and how it improves detection of key genes and transcripts.

715 **B.** Scatterplot showing differences in per-cell transcript capture (y-axis) as a function of aligned
716 reads per cell (x-axis) between 10x Genomics v2 (10x v2, grey) and Seq-Well S³ (black). Red
717 line indicates uniform line where transcripts per cell and aligned reads would be equivalent.

718 **C.** Scatterplot shows the differences in per-cell gene detection (y-axis) as a function of aligned
719 reads per cell (x-axis) between 10x v2 (grey) and Seq-Well S³ (black).

720 **D.** Scatterplot comparing gene detection rates in CD4⁺ T cells between 10x v2 (x-axis) and Seq-
721 Well S³ (y-axis). Black line indicates point of equivalence in gene detection frequency between
722 methods. Colors correspond to classes of genes including transcription factors (blue), cytokines
723 (magenta), and receptors (green).



724 **E.** Scatterplot comparing gene detection frequency (y-axis) between Seq-Well S³ (positive
725 values) and 10x v2 (negative values) as a function of the aggregate expression levels (log(scaled
726 UMI + 1)) of an individual gene (x-axis). Black line indicates point of equivalence in gene detection
727 frequency between methods. Colors correspond to classes of genes including transcription
728 factors (blue), cytokines (magenta), and receptors (green).

729 **F.** Violin plot (boxplots median +/- quartiles) showing the distribution of per-cell transcript capture
730 for Seq-well S³ (blue; n = 1,485), 10x v2 (red; n = 2995), and Smart-Seq2 (black, n = 382).


731 **G.** Scatterplot showing the relationship between aligned reads and genes detected per cell
732 between Seq-Well S³ (blue), 10x v2 (red) and Smart-Seq2 (black) in sorted PBMC CD4⁺ T cells.

733 **H.** Violin plots showing the distribution of normalized expression values for select transcription
734 factors, cytokines and cytokine receptors between Seq-Well S³ and 10x v2.


A



B



C



735 **Figure 2. Cell Types Recovered across Inflammatory Skin Conditions**

736 **A.** (Top-Left) Diagram illustrating the anatomic organization and major features of human skin.

737 (Top-Right) Cell-type composition of the epidermis and dermis. (Bottom) Sample processing


738 pipeline used to generate a collection cellular states across skin inflammation.

739 **B.** (Left) UMAP plot for 20,308 cells colored by cell-type cluster. (Right) Stacked barplot showing

740 the cell-type composition for each of the nine skin biopsies.

741 **C.** (Left) UMAP plot for 20,308 cells colored by inflammatory skin condition. (Right) Stacked

742 barplot showing the proportion of cells from each skin condition within phenotypic clusters.



743 **Figure 3. Identification of Inflammatory T cell States using Seq-Well S³**

744 **A.** (Left) Force-directed graph (Fruchterman Reingold) of 2,908 T cells colored by the nine
745 phenotypic sub-clusters identified by Louvain clustering. (Right) Stacked barplots showing the
746 distribution of these T cell sub-clusters within each skin biopsy.

747 **B.** (Left) Force-directed graph of 2,908 T cells colored by inflammatory skin condition. (Right)
748 Stacked barplots showing the contribution of each inflammatory skin condition to the T cell sub-
749 clusters.

750 **C.** T cell force-directed graphs displaying normalized expression ($\log(\text{scaled UMI} + 1)$) of a
751 curated group of sub-cluster-defining gene. Higher expression values are shown in black.


752 **D.** Heatmap showing normalized gene expression values ($\log(\text{scaled UMI} + 1)$) for a curated list
753 of sub-cluster-defining genes across nine T cell sub-clusters.

754 **E.** Heatmap showing the rate of detection for lineage-defining transcription factors, cytokines, and
755 cytokine receptors across T cell phenotypic clusters.

756 **F.** Heatmap showing average expression of genes enriched across T cells by inflammatory skin
757 condition (row-normalized average expression values).

758 **G.** Plot showing rates of detection of TCR genes from human skin T cells across a range of
759 sequencing depths.

760 **H.** Heatmap showing normalized gene expression values ($\log(\text{scaled UMI} + 1)$) for genes enriched
761 in sub-group analysis of T cell sub-cluster 8.



762 **Figure 4. Diverse Myeloid Cell States Uncovered using Seq-Well S³**

763 **A.** (Left) Force-directed graph of 2,371 myeloid cells colored by five phenotypic sub-clusters (NB,
764 Langerhans cells were enriched from leprosy and normal skin). (Right) Stacked barplots showing
765 the distribution of myeloid sub-clusters within each skin biopsy.

766 **B.** (Left) Force-directed graph of 2,371 myeloid cells colored by inflammatory skin condition.
767 (Right) Stacked barplots showing the contribution of each inflammatory skin condition to each
768 myeloid sub-cluster.

769 **C.** Force-directed graphs of 2,371 myeloid cells that highlighting expression of a curated group of
770 sub-cluster defining genes ($\log(\text{scaled UMI} + 1)$).


771 **D.** Heatmap showing the normalized expression ($\log(\text{scaled UMI} + 1)$) of a curated list of myeloid
772 cell-type cluster-defining genes.

773 **E.** Volcano plot showing genes differentially expressed in Langerhans cells between leprosy (n_{cells}
774 = 56) and normal skin (n_{cells} = 120). Log₁₀-fold change values are shown on the x-axis and -log₁₀
775 adjusted p-values are shown on the y-axis.

776 **F.** Heatmaps showing the normalized expression ($\log(\text{scaled UMI} + 1)$) of mast-cell proteases
777 across inflammatory skin conditions.

778 **G.** Heatmap showing detection frequencies for transcription factors, surface receptors, and
779 cytokines across DC sub-populations.

Figure 5.



780 **Figure 5. Keratinocyte Differentiation Trajectories**

781 **A.** Diagram showing the layers of the epidermis and morphologic changes associated with
782 keratinocyte differentiation.

783 **B.** UMAP embedding of 20,308 cells with all keratinocyte and hair follicle populations highlighted
784 in blue.

785 **C.** Diffusion map of 5,141 keratinocytes colored by inflammatory skin condition. Axes correspond
786 to diffusion components.

787 **D.** t-SNE plot showing differentiation trajectory of keratinocytes from normal skin from basal cells
788 (yellow) through differentiating cells (aqua) and terminal keratinocytes (purple).

789 **E.** (Top-left) tSNE plot of normal keratinocytes with normalized *KRT14* expression values
790 overlaid. (Top-right) Immunohistochemistry staining showing the expression of *KRT14* from the
791 human protein atlas (Uhlén et al., 2015). (Bottom-left) tSNE plot of normal keratinocytes with
792 normalized *FLG* expression values overlaid. (Bottom-right) Immunohistochemistry staining of
793 *FLG* from the human protein atlas(Uhlén et al., 2015). Scale bars = 50 microns.

794 **F.** Stacked barplot showing genes with the highest differential pseudo-time correlation between
795 normal keratinocytes (blue) and psoriatic keratinocytes (red) sorted by correlation values in
796 psoriatic keratinocytes. Correlation values shown on the x-axis represent Pearson correlation
797 coefficients between normalized gene expression and diffusion pseudotime.


798 **G.** (Top) Immunofluorescence staining in normal (above) and psoriatic (below) for FOSL, IL36G,
799 TNFAIP3, and APOBEC3. All images stained for nuclei (DAPI) and gene of interest (Red
800 Fluorescence). Scale bar = 100 microns.

801 **H.** Immunofluorescence staining for IL-17R expression (green) in normal (left), uninvolved
802 (middle), and psoriatic skin (right). Scale bar = 100 microns.

Figure S1.


A

1. mRNA Capture




Cell Barcode
UMI

2. First Strand Synthesis




3. Template Switching


Successful Template Switching




Failed Template Switching



4. Denature RNA Template




5. Second Strand Synthesis




B

Library Complexity - Cell Lines




C

Library Complexity - Human PBMCs




D

Transcript Purity in Species Mixing
Seq-Well Protocol V1




B

Optimization - Cell Lines




C

Optimization - Human PBMCs



D

Seq-Well Protocol S^3



803 **Supplementary Figure 1. Second-Strand Synthesis Overview, related to Figure 1**


804 **A.** Illustration of the second strand synthesis procedure: (1) mRNA is captured via poly-T priming
805 of poly-adenylated mRNA; (2) First strand synthesis is performed to generate single-stranded
806 cDNA template on bead-bound sequences; (3) Successful template switching: The use of
807 enzymes with terminal transferase activity generates a 3' overhang of 3 cytosines. Template
808 switching utilizes this overhang to append the SMART sequence to both ends of the cDNA
809 molecule during first strand synthesis. Failed Template Switching: If template switching fails, this
810 results in loss of previously primed and reverse transcribed mRNA molecules; (4) mRNA template
811 is chemically denatured using 0.1M NaOH; (5) Second strand synthesis is performed using a
812 random-octamer with the SMART sequence in the 5' orientation; and, (6) Following second strand
813 synthesis, PCR amplification, library preparation and sequencing are performed to generate data.

814 **B.** Scatterplots show the relationship between transcript detection (y-axis) and number of aligned
815 reads per cell (x-axis) for an initial experiment (top) series of optimization conditions using
816 HEK293 and NIH-3T3 cell lines (bottom).

817 **C.** Scatterplots that illustrate the relationship between number of transcripts detected (y-axis) and
818 number of aligned reads per cell (x-axis) between Seq-Well V1 and Seq-Well S³ in sequencing
819 experiments for an initial experiment (top) and a series of optimization experiment using human
820 PBMCs (bottom).

821 **D.** Histograms that show the fraction of transcripts uniquely mapped to the human genome for
822 each cell for Seq-Well V1 (Top) and Seq-Well S³ (Bottom). Colors indicate species classification
823 for cells with at least 90% purity of human (blue) or mouse (red) mapping.

Figure S2.



824 **Supplementary Figure 2. PBMC Methods Comparisons, related to Figure 1**

825 **A.** t-SNE plot showing detected cell-types among PBMCs including CD4⁺ T cells (green),
826 CD8⁺/NK Cells (blue), B cells (purple), and Monocytes (red) using 10X v2 and Seq-Well S³. Cells
827 recovered using Seq-well are colored with darker shades.

828 **B.** Stacked barplots show the proportion of cell types recovered using Seq-Well S³ (left) and
829 10X v2 (right).


830 **C.** Top: Violin plots (boxplots median +/- quartiles) showing the distribution of per cell gene
831 detection from Seq-Well S³ (left) and 10X v2 (right). Bottom: Violin plots (boxplots median +/-
832 quartiles) showing the distribution of per cell-gene detection from Seq-Well S³ (left) and 10X v2
833 (right).

834 **D.** Scatterplots showing a comparison of gene detection frequencies between Seq-Well S³ (y-
835 axis) and 10x v2 (x-axis) for each cell type.

836 **E.** Scatterplots showing the difference in gene detection between Seq-Well S³ and 10X v2 (y-
837 axis) as a function of average normalized expression ($\log(\text{scaled UMI} + 1)$) (x-axis).

838 **F.** Scatterplots showing a comparison of gene detection frequencies among sorted CD4⁺ T cells
839 between **(Left)** Seq-well S³ (y-axis) and 10x v2 (x-axis), **(Middle)** Seq-Well S³ (y-axis) and
840 Smart-Seq2 (x-axis), and **(Right)** 10x v2 (y-axis) and Smart-Seq2 (x-axis).

Figure S1



841 **Supplementary Figure 3. Overview of Samples, related to Figure 2**


842 **A.** UMAP plot for 20,308 cells colored by 33 cell type cell type clusters (Louvain Resolution: 2.0).

843 **B.** Heatmap showing the relative expression of cell-type defining gene signatures across 20,308
844 cells.

845 **C.** Dendrogram of hierarchical clustering shows similarity of cell type clusters among top 25
846 cluster-defining genes (**Figure S3B**).

847 **D.** t-SNE plots for each of the nine skin biopsies colored by generic cell type.

848 **E.** Violin plots show the distribution of per-cell quality metrics displayed in UMAP embedding of
849 20,308 cells colored by colored generic cell-type classification (**Figure 2B**).



850 **Supplementary Figure 4. Immune Cell Heterogeneity, related to Figures 3 and 4**

851 **A.** (Top) Force-directed graph of 2,903 T cells colored by T cell sub-cluster. (Bottom) Heatmap
852 of gene-set enrichment scores based on comparison of T cell phenotypic sub-clusters to a curated
853 list of reference signatures in the Savant database.

854 **B.** Sub-grouping results for (top) T cell sub-cluster 0 and (bottom) T cell sub-cluster 8. For each
855 analysis, t-SNE plots colored by inflammatory skin condition (top-left) and sub-cluster (bottom-
856 left) are shown. For each clusters, heatmaps show gene expression patterns across T and NK
857 cells sub-types (right).

858 **C.** (Top) Detection rates for TCR genes for PBMCs in Seq-Well v1, 10x v2. and Seq-Well S³.
859 (Bottom) Detection frequency of TCR V-J (e.g. TRAV/J and TRBV/J) genes in CD4⁺ T cells from
860 peripheral blood between Seq-Well S³ (y-axis) and 10x v2 (x-axis). Colors correspond to TRAJ
861 (red), TRAV (green), TRBJ (blue), and TRBV (purple) genes.

862 **D.** Force-directed graph of 2,371 myeloid cells colored by myeloid phenotypic sub-clusters.

863 **E.** Heatmap of gene-set enrichment scores based on comparison of myeloid phenotypic sub-
864 clusters to a curated list of reference signatures in the Savant database.


865 **F.** (Left) UMAP plot for 502 dendritic cells from human skin colored by phenotypic sub-grouping.
866 (Right) Stacked barplot showing composition of dendritic cells within each of nine skin biopsies
867 by DC sub-cluster.

868 **G.** (Left) UMAP plot for 502 dendritic cells from human skin colored by inflammatory skin
869 condition. (Right) Stacked barplot showing contribution of inflammatory skin conditions to each
870 dendritic cell sub-grouping.

871 **H.** Heatmap showing average signature score across 5 dermal DC populations based on dendritic
872 cell signatures from *Villani et al. Science 2017*.

873 **I.** Heatmap showing the distribution of normalized gene expression levels ($\log(\text{scaled UMI} + 1)$)
874 for cluster-defining genes across dermal DC subpopulations.

875 **J.** UMAP plots colored by normalized expression levels for DC sub-grouping-defining genes.



876 **Figure S5. Stromal Cell Diversity**

877 **A.** Force-directed plots for 4,996 endothelial cells colored by phenotypic sub-cluster (left) and
878 stacked barplot showing the distribution of endothelial phenotypic sub-clusters across samples
879 (right).

880 **B.** Force-directed plots for 4,996 endothelial colored by inflammatory skin condition (left) and
881 stacked barplot showing the contribution of each inflammatory skin condition to endothelial
882 phenotypic sub-clusters.

883 **C.** Forced-directed plot colored by normalized expression level of genes that mark endothelial cell
884 types: (Left) CD93, venules, (Middle) TAGLN, arterioles, (Right) LYVE1, lymphatics.

885 **D.** Heatmap showing patterns of normalized gene expression levels ($\log(\text{scaled UMI} + 1)$) across
886 7 clusters of endothelial cells.

887 **E.** Heatmap showing row-normalized expression levels of vascular addressins across phenotypic
888 sub-clusters of endothelial cells.


889 **F.** Force-directed plots for 4,189 fibroblasts colored by phenotypic sub-cluster (left) and stacked
890 barplot showing the distribution of fibroblast phenotypic sub-clusters across samples (right).

891 **G.** Force-directed plots for 4,189 fibroblasts colored by inflammatory skin condition (left) and
892 stacked barplot showing the contribution of each inflammatory skin condition to fibroblast
893 phenotypic sub-clusters.

894 **H.** Force-directed graphs highlighting fibroblast cluster defining genes.

895 **I.** Heatmap showing the normalized gene expression levels ($\log(\text{scaled UMI} + 1)$) of fibroblast
896 cluster-defining genes.

Figure 3



897 **Supplementary Figure 6. Keratinocyte Differentiation Trajectories, related to Figure 5**

898 **A.** (Left) Heatmap showing enrichment of genes along pseudo-temporal trajectories for normal
899 keratinocytes. (Right) Heatmap showing enrichment of genes along pseudo-temporal trajectories
900 among psoriatic keratinocytes.

901 **B.** Differentiation trajectories for Normal (left) and Psoriatic (right) keratinocytes.

902 **C.** Violin plots showing localization of cytokine response signatures in basal, differentiating and
903 terminal keratinocytes for Normal (left) and Psoriatic (right) keratinocytes.